Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 3/20 | 0.48 |
| ▸ | PARP1 | P09874 | 10/20 | 0.46 |
| ▸ | ATR | Q13535 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652419 | 0.88 | HPSE (0.57) | MAPK8FLT3PARP1KDM4EHSD17B10 | |
| SCHEMBL5647867 | 0.84 | TSHR (0.49) | FLT3PARP1KDM4EHSD17B10RAD52 | |
| SCHEMBL5653408 | 0.84 | FLT3 (0.48) | MAPK8FLT3PARP1KDM4EHSD17B10 | |
| SCHEMBL5649940 | 0.83 | FLT3 (0.48) | MAPK8FLT3KDM4EHSD17B10 | |
| SCHEMBL5651896 | 0.83 | FLT3 (0.48) | MAPK8FLT3KDM4EHSD17B10 | |
| SCHEMBL5649669 | 0.82 | MAPK8 (0.48) | MAPK8FLT3ATRKDM4EHSD17B10 | |
| SCHEMBL5651511 | 0.81 | KDM4E (0.54) | PARP1KDM4E | |
| SCHEMBL5651343 | 0.81 | FLT3 (0.46) | FLT3PARP1 | |
| SCHEMBL5651490 | 0.80 | FLT3 (0.45) | FLT3KDM4EHSD17B10HDAC3HDAC1 | |
| SCHEMBL5652034 | 0.79 | FLT3 (0.58) | MAPK8FLT3ATRKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | MAPK8 1856/4885FLT3 1968/4885PARP1 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.